An Analysis of Toxicities and Time to Engraftment Associated with Three Distinct Melphalan Treatment Schemas in Patients with Multiple Myeloma Receiving Autologous Hematopoetic Stem Cell Transplantation.

被引：0
|
作者：
Maewal, Ila [1 ]
Kurtzweil, Andy J. [1 ]
Shapiro, Jamie F.
Westmoreland, Michael D. [1 ]
Bassett, Roland L. [2 ]
Giralt, Sergio
机构：
[1] Univ Texas MD Anderson Canc Ctr, Div Pharm, Houston, TX 77030 USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Houston, TX USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：753 / 753
页数：1
相关论文
共 50 条
  • [41] Impact of Neoplastic Plasma Cells in the Stem Cell Collection on Multiple Myeloma Patients Receiving Autologous Stem Cell Transplantation
    Xu, Jingyu
    Li, Lingna
    Yan, Wenqiang
    Fan, Huishou
    Liu, Jiahui
    Du, Chenxing
    Deng, Shuhui
    Sui, Weiwei
    Xu, Yan
    Qiu, Lugui
    An, Gang
    BLOOD, 2022, 140 : 10011 - 10012
  • [42] Impact of residual tumor cells in the stem cell collection on multiple myeloma patients receiving autologous stem cell transplantation
    Xu, Jingyu
    Yan, Wenqiang
    Fan, Huishou
    Liu, Jiahui
    Li, Lingna
    Du, Chenxing
    Deng, Shuhui
    Sui, Weiwei
    Xu, Yan
    Qiu, Lugui
    An, Gang
    ANNALS OF HEMATOLOGY, 2023, 102 (11) : 3195 - 3204
  • [43] The efficacy of high-dose melphalan with autologous peripheral blood stem cell transplantation in patients with multiple myeloma
    Lee, JL
    Kim, SB
    Lee, GW
    Ryu, MH
    Kim, E
    Kim, S
    Kim, WK
    Lee, JS
    Kim, SH
    Suh, C
    YONSEI MEDICAL JOURNAL, 2003, 44 (05) : 800 - 810
  • [44] Population Pharmacokinetics and Bayesian Estimation of Melphalan Concentrations in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
    Mizuno, K.
    Dong, M.
    Fukuda, T.
    Anaissie, E. J.
    Vinks, A. A.
    THERAPEUTIC DRUG MONITORING, 2013, 35 (05) : 708 - 709
  • [45] Bortezomib and Melphalan (Bor/MEL) Conditioning for Patients with Multiple Myeloma Undergoing Single Autologous Stem Cell Transplantation
    Zepeda, Victor H. Jimenez
    Duggan, Peter
    Neri, Paola E.
    Bahlis, Nizar J.
    BLOOD, 2014, 124 (21)
  • [46] Autologous stem cell transplantation with high dose melphalan conditioning regimen is safe for elderly multiple myeloma patients
    Czyz, Anna
    Szeremet, Agnieszka
    Bogucka-Fedorczuk, Aleksandra
    Majcherek, Maciej
    Rybka, Justyna
    Prajs, Iwona
    Wrobel, Tomasz
    BONE MARROW TRANSPLANTATION, 2019, 54 : 499 - 500
  • [47] Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma
    Buadi, Francis K.
    Gertz, Morie A.
    Laplant, Betsy R.
    Halvorson, Alese
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Dingli, David
    Kapoor, Prashant
    Gonsalves, Wilson I.
    Miceli, Teresa
    Brandes, Eva
    Stafford, Scott L.
    Martenson, James A.
    Hogan, William J.
    Kumar, Shaji K.
    BLOOD, 2016, 128 (22)
  • [48] Impact of Obesity in Patients with Multiple Myeloma Receiving High-Dose Melphalan Followed By Autologous Hematopoietic Cell Transplantation
    Frimpong, Justina Ofori
    Tombleson, Rebecca
    Alsina, Melissa
    Shapiro, Jamie
    Kim, Jongphil
    Yue, Binglin
    Perkins, Janelle
    Nishihori, Taiga
    BLOOD, 2016, 128 (22)
  • [49] Maintenance treatment after autologous stem cell transplantation in patients with multiple myeloma - new drugs for multiple myeloma
    Maiolino, Angelo
    Garnica, Marcia
    LEUKEMIA RESEARCH, 2018, 73 : S3 - S4
  • [50] Evomela® Significantly Increases the Risk of Engraftment Syndrome in Patients with Multiple Myeloma Treated with Autologous Stem Cell Transplantation
    McKenna, Marshall
    McKiernan, Phyllis
    Siegel, David S.
    Rowley, Scott D.
    Biran, Noa
    Vesole, David H.
    Goldberg, Stuart L.
    Nyirenda, Themba
    Pecora, Andrew L.
    Goy, Andre
    Donato, Michele L.
    BLOOD, 2019, 134
12345